D. Western Therapeutics Institute, Inc. (TYO:4576)

Japan flag Japan · Delayed Price · Currency is JPY
99.00
-1.00 (-1.00%)
Mar 6, 2026, 3:30 PM JST
Market Cap5.37B -7.2%
Revenue (ttm)387.62M -17.7%
Net Income-632.09M
EPS-13.19
Shares Out54.25M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume444,800
Average Volume674,105
Open100.00
Previous Close100.00
Day's Range98.00 - 101.00
52-Week Range87.00 - 181.00
Beta-0.10
RSI48.33
Earnings DateFeb 13, 2026

About TYO:4576

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocain... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 21
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4576
Full Company Profile

Financial Performance

In 2025, TYO:4576's revenue was 387.62 million, a decrease of -17.70% compared to the previous year's 471.00 million. Losses were -632.09 million, -51.00% less than in 2024.

Financial Statements